Dr Gwendolyn Henderson Parker, MD | |
48165 Liberty Dr, Shelby Twp, MI 48315-4061 | |
(313) 448-6780 | |
(866) 648-5525 |
Full Name | Dr Gwendolyn Henderson Parker |
---|---|
Gender | Female |
Speciality | Radiology - Radiation Oncology |
Location | 48165 Liberty Dr, Shelby Twp, Michigan |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1811444235 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2085R0001X | Radiology - Radiation Oncology | 4301405408 (Michigan) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Gwendolyn Henderson Parker, MD 600 E. Lafayette Blvd, Mc 504d C/o Bcbsm, Detroit, MI 48226-2998 Ph: (313) 448-6780 | Dr Gwendolyn Henderson Parker, MD 48165 Liberty Dr, Shelby Twp, MI 48315-4061 Ph: (313) 448-6780 |
News Archive
Researchers at Duke University Medical Center may finally have discovered why people with sickle cell disease get milder cases of malaria than individuals who have normal red blood cells.
CSL Behring announced today that it has been granted Orphan Drug Designations by the European Commission for the development of its recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP), a novel therapy to treat hemophilia A and hemophilia B patients with inhibitors.
In 2010, lucy activewear has committed to make a donation to Off the Mat, Into the World®, a non-profit co-founded by international yoga instructor Seane Corn, to support Off the Mat's mission of inspiring conscious, sustainable community service through the power of yoga.
As a cell moves forward, physical stress on its skeleton triggers molecular fingers and arms to grasp each other in reinforcing links that stabilize the skeleton, according to images produced by investigators at St. Jude Children's Research Hospital.
Optimer Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2010. Optimer reported a net loss for the third quarter of 2010 of $11.8 million, or $0.30 per share, which was in line with the Company's expectations. This compares to a net loss for the third quarter of 2009 of $9.4 million, or $0.28 per share. The increase in net loss was primarily due to an increase in research and development and marketing expenses.
› Verified 1 days ago